Mineralys Therapeutics, Inc. (MLYS) Misses Q4 EPS by 27c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q4 EPS of ($0.98), $0.27 worse than the analyst estimate of ($0.71).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• AI and memory not a classic bubble, but future returns uncertain - strategist
• Roblox (RBLX), Unity Software Inc. (U) Falls on Reports Meta to Let You Build Games with AI on Your Phone
• Alaska Air expects Boeing 737 MAX 10 certification this month